Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | CASP7 | P55210 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.44 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955934 | 1.00 | ALDH1A1 (0.53) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| Hydrochloric Acid SCHEMBL27466069 | 0.98 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| 8-Aminoquinoline SCHEMBL2909622 | 0.85 | ERN1 (0.42) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL29953906 | 0.85 | NPC1 (0.60) | ALDH1A1MEN1KMT2ACASP1HTT | |
| SCHEMBL496860 | 0.85 | NPC1 (0.60) | ALDH1A1MEN1KMT2ACASP1HTT | |
| Quinoline SCHEMBL28319703 | 0.84 | ALDH1A1 (0.59) | ALDH1A1MEN1KMT2ACASP1HTT | |
| SCHEMBL27765162 | 0.83 | NPC1 (0.58) | ALDH1A1MEN1KMT2ACASP1HTT | |
| SCHEMBL5620728 | 0.82 | HTT (0.60) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL6651332 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ACASP1CASP7 | |
| SCHEMBL6651334 | 0.82 | ALDH1A1 (0.47) | ALDH1A1MEN1KMT2ACASP1CASP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 585 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113164458-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-13 | — | — | CN | claimed |
| CN-113164458-A | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-110049985-A | HETEROCYCLIC SULFONES AS ROR GAMMA MODULATORS | 百时美施贵宝公司 | 2019-07-23 | — | — | CN | claimed |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | BASF SE (DE) | 2019-03-05 | — | — | US | claimed |
| US-20170012208-A1 | ORGANIC SEMICONDUCTOR FORMULATIONS | USINVEST LLC | 2017-01-12 | — | — | US | claimed |
| CN-101137655-A | Androgen receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2008-03-05 | — | — | CN | claimed |
| CN-1245977-C | Liposomal antineoplastic drugs and uses thereof | INEX PHARMACEUTICALS CORP (CA) | 2006-03-22 | — | — | CN | claimed |
| CN-1391576-A | Androgen receptor modulator compounds and methods | LIGAND PHARM INC (US) | 2003-01-15 | — | — | CN | claimed |
| CN-1044242-C | Heterocyclic-cyclic amine derivatives | PFIZER (US) | 1999-07-21 | — | — | CN | claimed |
| CN-1065267-A | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER (US) | 1992-10-14 | — | — | CN | claimed |
| US-4778802-A | PSYCHOTROPIC ACTIVITY; ANTIDEPRESSANTS | JOHN WYETH & BROTHER, LTD. (GB) | 1988-10-18 | — | — | US | claimed |
| EP-4720057-A2 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | PHARMABLOCK SCIENCES (NANJING) , INC. (CN) | 2025-12-02 | — | — | US | disclosed |
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CULLGEN SHANGHAI INC (CN) | 2025-10-23 | — | — | US | disclosed |
| EP-4573086-A1 | METHANOGEN INHIBITORS | Agrizeronz Limited Partnership (NZ) | 2025-06-25 | — | — | EP | disclosed |
| CN-1065267-A | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER (US) | 1992-10-14 | — | — | CN | disclosed |
| WO-1992016104-A1 | LEUKOTRIENE ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1992-10-01 | — | — | WO | disclosed |
| CN-1042912-A | (1H-oxazol-1-ylmethyl) substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA NV (BE) | 1990-06-13 | — | — | CN | disclosed |
| EP-0371564-A2 | (1H-azol-1-ylmethyl)substituted quinoline, quinazoline or quinoxaline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-06-06 | — | — | EP | disclosed |
| US-4344956-A | Oxotetrahydrothiophenes | ERCOLI NICOLO | 1982-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325678-A1 | CYCLIC-AMP RESPONSE ELEMENT BINDING PROTEIN (CBP) AND/OR ADENOVIRAL E1A BINDING PROTEIN OF 300 KDA (P300) DEGRADATION COMPOUNDS AND METHODS OF USE | CREBBP, EP300, CREB1 | ALDH1A1 4417/4885MEN1 3103/4885KMT2A 2044/4885 |
| US-10224485-B2 | Process for preparing a crystalline organic semiconductor material | STOM, SPOP, TTR | ALDH1A1 4757/4885MEN1 722/4885KMT2A 3227/4885 |
| US-12486251-B2 | CBP/EP300 inhibitor and use thereof | EP300, CREBBP, BPTF | ALDH1A1 2314/4885MEN1 2211/4885KMT2A 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.